Namida Lab Partners with Heartland Pharmacy to offer COVID-19 Antibody Test to Northwest Arkansas

Much Anticipated Antibody Test Now Available to General Public

Fayetteville, AR: (June 18, 2020) Namida Lab announced the launch of its partnership with Heartland Pharmacy to offer Namida’s COVID-19 antibody testing to the general public. Namida Lab will use Heartland Pharmacy’s Fayetteville and Rogers locations as initial collection sites for antibody testing to the residents of Northwest Arkansas with future expansions to include Heartland’s other locations in Northwest Arkansas as well as their pharmacies in Central Arkansas and the River Valley. These antibody testing services are arriving on the heels of Northwest Arkansas’ largest weekly increase in COVID-19 cases since the beginning of the pandemic. Antibody testing differs from the commonly known “swab” test (PCR) in that it does not indicate the current presence of COVID-19. Antibody testing determines whether you’ve had COVID-19 in the past and whether you’ve developed antibodies against the virus. As cases continue to rise, having the knowledge of exposure to the coronavirus can allow the people of NWA to make more educated choices moving into the next few months of statewide relaxation of restrictions.

Omid Moghadam, CEO of Namida Lab Inc., believes that the market is more than ready for these services: 

“Since we started offering our COVID-19 antibody test to large employers last month, we have been inundated with calls from the public inquiring about the availability of the test to individuals,” says Mr. Moghadam. “Today, we are happy to announce the availability of our test to the public through a partnership with Heartland Pharmacy.”

To make an appointment for antibody testing, please visit https://namidalab.com/antibody-test

About Namida Lab: Namida Lab Inc. is an Arkansas-based biotech company specializing in biomarker-based testing. Namida has assembled a talented team with experience across the diagnostic, medical information and scientific automation fields to develop a diagnostic platform leveraging the untapped power of tears. Namida’s first product, Melody®, a screening assay for breast cancer based on proteins isolated from tear fluid, will launch later this year.